Testosterone replacement therapy and voiding dysfunction.
about
Amelioration of sexual behavior and motor activity deficits in a castrated rodent model with a selective androgen receptor modulator SARM-2f.Hypogonadal men with moderate-to-severe lower urinary tract symptoms have a more severe cardiometabolic risk profile and benefit more from testosterone therapy than men with mild lower urinary tract symptoms
P2860
Testosterone replacement therapy and voiding dysfunction.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Testosterone replacement therapy and voiding dysfunction.
@en
Testosterone replacement therapy and voiding dysfunction.
@nl
type
label
Testosterone replacement therapy and voiding dysfunction.
@en
Testosterone replacement therapy and voiding dysfunction.
@nl
prefLabel
Testosterone replacement therapy and voiding dysfunction.
@en
Testosterone replacement therapy and voiding dysfunction.
@nl
P2860
P356
P1476
Testosterone replacement therapy and voiding dysfunction.
@en
P2093
Tobias S Köhler
Wesley Baas
P2860
P304
P356
10.21037/TAU.2016.08.11
P577
2016-12-01T00:00:00Z